Markets

ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher

ImmunoGen, Inc.IMGN was a big mover last session, as the company saw its shares jump above 14% on the day. The upside took place after it released abstracts for the current year's American Society of Clinical Oncology (ASCO) meeting, followed by a press release of the updated data. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $3.58 to $4.73 in the past one-month time frame.

The company has seen four positive and one negative estimate revisions in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

ImmunoGen currently carries a Zacks Rank #3 (Hold).

ImmunoGen, Inc. Price

ImmunoGen, Inc. Price | ImmunoGen, Inc. Quote

A top-ranked stock in the Medical-Drugs industry is Aerie Pharmaceuticals, Inc. AERI sporting a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Is IMGN going up? Or down? Predict to see what others think: Up or Down

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ImmunoGen, Inc. (IMGN): Free Stock Analysis Report

Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AERI IMGN

Other Topics

Investing Stocks

Latest Markets Videos